BridgeBio plots path to market for muscular dystrophy drug after posting phase 2 data

BridgeBio Pharma has posted an upbeat update on its limb-girdle muscular dystrophy type 2i (LGMD2i) program. With a phase 2 trial linking BBP-418 to positive biomarker changes, BridgeBio is preparing to talk to regulators about paths to market for the treatment of muscle wasting in the arms and legs.